Dangerous secrets and Monkey Business: On whose shoulders do we stand?

Suzanne Humphries MD

NOVEMBER 2025

Austin Texas

Dangerous secrets and Monkey Business: On whose shoulders do we stand?

Suzanne Humphries MD

NOVEMBER 2025

Austin Texas

MONKEY VIRUS IN KIDNEY BIOPSIES

Table 4. Detection of SV40 genome in renal biopsies

Diagnosis	*n*	Age	SV40+
Idiopathic FSGS 60%	10	56 ± 13	6/10
Collapsing FSGS 60%	10	43 ± 13	6/10
HIV-associated FSGS 50%	10	37 ± 12	5/10
All FSGS 56%	30		17/30
Membranous nephropathy 20%	10	55 ± 11	2/10
Minimal change disease 20%	10	47 ± 16	2/10

"This study demonstrates for the first time that human kidney can serve as a reservoir for SV40 replication and that SV40 may contribute to the pathogenesis of kidney disease, particularly FSGS."

Li JASN 2002 PMID: 12191976

1960 FOUNDATIONAL STRAIN OF POLIO VIRUS PASSAGE HISTORY 1954-1960

- 14 living monkeys, 2 cultures of monkey testicles
- THEN 9 more passages monkey testicles
- THEN 15 more passages in monkey testicle
- THEN 18 passages in monkey kidney
- THEN 2 passages through living rhesus monkey skin
- THEN More passage African Green monkey skin and kidney
- THEN 7 cultures African Green kidney cells
- THEN Rhesus monkey kidney

*TRANSFORMATION INDUCED BY SIMIAN VIRUS 40 IN HUMAN RENAL CELL CULTURES, I. MORPHOLOGY AND GROWTH CHARACTERISTICS**

By Harvey M. Shein† and John F. Enders

RESEARCH DIVISION OF INFECTIOUS DISEASES, CHILDREN'S HOSPITAL MEDICAL CENTER, BOSTON, AND DEPARTMENT OF BACTERIOLOGY AND IMMUNOLOGY, HARVARD MEDICAL SCHOOL, BOSTON

Communicated May 22, 1962

Shein 1962 PMID: 13911592

TRANSFORMATION INDUCED BY SIMIAN VIRUS 40 IN HUMAN RENAL CELL CULTURES, II. CELL-VIRUS RELATIONSHIPS*

By Harvey M. Shein,† John F. Enders, and Jeana D. Levinthal

RESEARCH DIVISION OF INFECTIOUS DISEASES, THE CHILDREN'S HOSPITAL MEDICAL CENTER, BOSTON, AND THE DEPARTMENT OF BACTERIOLOGY AND IMMUNOLOGY, HARVARD MEDICAL SCHOOL

Shein 1962 PMID 13911590

Kidney Cancer (C64-C66,C68): 1975-2011
European Age-Standardised Incidence Rates per 100,000 Population, by Age, Persons, Great Britain



Please include the citation provided in our Frequently Asked Questions when reproducing this chart: http://info.cancerresearchuk.org/cancerstats/faqs/#How

Prepared by Cancer Research UK

Original data sources:

1. Office for National Statistics. Cancer Statistics: Registrations Series MB1. http://www.ons.gov.uk/ons/search/index.html?newquery=series+mb1
2. Welsh Cancer Intelligence and Surveillance Unit. http://www.wcisu.wales.nhs.uk
3. Information Services Division Scotland. Cancer Information Programme. www.isdscotland.org/cancer

CANCER RESEARCH UK

Kidney Cancer over time

LONG-TERM FOLLOW-UP OF PERSONS INADVERTENTLY INOCULATED WITH SV40 AS NEONATES

EDWARD A. MORTIMER, JR., M.D.,

- 1073 SV40 vaccine exposed infants from 1960-62
- 95% still followed after 17 years
- 87% followed after 19 years

"Because of the mounting complexities and obstacles in tracing this particular group of subjects and the negative results to date, surveillance has been terminated."

Mortimer 1981 NEJM: PMID 6272114

ADVENTITIOUS AGENTS: DEFINITION

- Unintentional
- Pathogenic (disease causing)



There were **at LEAST** four teams who tried to make an anti-SV40 vaccine.

- Bernice Eddy and Sarah Stewart, DBS.
- Goldner and Maurice Hilleman, Merck
- Martin Sands and Michael Imperiale, Michigan Med school
- Harvey Pass, Karmanos Cancer institute, Wayne State University

Goldner 1963
PMID: 14101216

Attempts to Interrupt Virus Tumorigenesis by Immunization Using Homologous "Bjorklund-Type" Antigen.* (28704)

H. Goldner, A. J. Girardi and M. R. Hilleman
Division of Virus and Cell Biology Research, Merck Institute for Therapeutic Research, West Point, Pa.

Studies were undertaken in our laboratory to ascertain whether homologous lipoprotein tumor antigen, prepared according to Bjorklund, could interrupt the appearance of tumors in animals infected at birth with oncogenic viruses. In the experiments, both the polyoma- and SV_{40}-hamster tumor systems were employed. "Bjorklund-type" lipoprotein antigen vaccine, prepared from corresponding virus-induced tumors, was given in incomplete Freund's adjuvant and in aqueous

suspension during the time interval between virus inoculation and the first appearance of tumors. In addition, uninoculated adult hamsters were injected with such antigens prior to homologous transplant tumor or malignant cell culture challenge. Except for one example, no apparent protective effect was afforded. Instead, evidence for possible immunologic enhancement of tumorigenesis was obtained.

The phenomenon of enhanced tumor-take in animals, on an immunologic basis. is neither new nor unique in studies of oncogenesis. Working with the mouse sarcoma system, Kaliss(24-26) has shown that a humoral antibody response to tumor antigen may effect tumor enhancement in contrast to a cellular response which results in rejection. These phenomena have been demon-

present experiments in animals, it is nevertheless true that the apparent immunologic enhancing effect was not expected. This might provide some theoretical basis, at least, for caution where immunization of the human subject is concerned.



https://www.zotero.org/foxsayswhat/library

X @pizzapicklespur



Humphries 2025


Heng
SV40
COVID-19


SMALL POX &
THE FIRST VACCINE

IN HONOR OF:

Dr Bernice Eddy

Dr J Anthony Morris

Judyth Vary Baker

Dr Bernice Eddy

Dr Sarah Srewart

VIROLOGY
MONOGRAPHS

7

BERNICE E. EDDY
POLYOMA VIRUS

E. NORRBY
RUBELLA VIRUS

SPRINGER-VERLAG NEW YORK INC.

Worthless Vaccines passed by DBS

- Senator PERCY. Doctor, right at the outset of your testimony, you make reference to the General Accounting Office report, that 32 vaccines of no known value, and some possible harm, have continued to be licensed.

WORTHLESS VACCINES

I have never seen a figure as to what the total dollar value of those vaccines would be. What was the cost of the vaccines, which were either of little value or perhaps even harmful, and which were administered to people who felt they were being protected?

Dr. ISAACSON. Well, I think it must be astronomical. I do not think I could give you an actual figure. Since some of these appear from the investigation to have been on the market for 20 years, certainly it must add up.

Consumer Safety Act of 1972, Hearings before the subcommittee on executive reorganization and government research, 92nd congress, second session, S. 3419, April 20, 23, and May 3, 4, pg 346

VACCINES REFERRED TO AS INEFFFECTIVE BY THE DBS DIRECTOR AND THEIR MANUFACTURERS

	Product listed in report	Brand name of product listed in report	Manufacturer
1.	Product A	Bacterial vaccine mixed respiratory	Hollister-Stier Laboratories.
2.	Product B	Respiratory UBA	Eli Lilly & Co.
3.	Product C	Staphylococcus-streptococcus UBA	Do.
4.	Product D	Combined vaccine No. 4 with catarrhalis	Do.
5.	Product E	Mixed vaccine No. 4 with H. influenzae	Do.
6.	Product F	Staphylococcus vaccine	Do.
7.	Product G	Entoral	Do.
8.	Product H	Typhoid H. antigen	Do.
9.	Product I	Vacagen tablets	Merck, Sharp, & Dohme.
10.	Product J	Brucellin antigen	Do.
11.	Product K	Staphylo-strepto serobacterin vaccine	Do.
12.	Product L	Catarrhalis serobacterin vaccine mixed	Do.
13.	Product M	Sensitized bacterial vaccine H. influenzae serobacterin in vaccine mixed.	Do.
14.	Product N	Staphage lysate type I	Delmont Laboratories, Inc.
15.	Product O	Staphage lysate type III	Do.
16.	Product P	Staphage lysate types I and III	Do.
17.	Product Q	Catarrhalis combined vaccine	Merrell-National Laboratories (division, Richardson-Merrell).
18.	Product R	Strepto-staphylo vatox	Merrell-National Laboratories.
19.	Product S	Staphylococcus toxoid-vaccine vatox	Do.
20.	Product T	Respiratory vatox	Do.
21.	Product U	Respiratory B.A.C.	Hoffman Laboratories, Inc.
22.	Product V	Gram-negative B.A.C.	Do.
23.	Product W	Pooled stock B.A.C. No. 1	Do.
24.	Product X	Pooled stock B.A.C. No. 2	Do.
25.	Product Y	Staphylococcal B.A.C.	Do.
26.	Product Z	Pooled skin B.A.C	Do.
27.	Product AA	Mixed infection phylacogen	Parke, Davis & Co.
28.	Product BB	Immunovac oral vaccine	Do.
29.	Product CC	Immunovac respiratory vaccine (parenteral)	Do.
30.	Product DD	Streptococcus immunogen arthritis	Do.
31.	Product EE	N. catarrhalis vaccine (combined)	Do.
32.	Product FF	N. catarrhalis vaccine immunogen (combined)	Do.

Dwight D. Eisenhower (34th, 1953-1961)

John F. Kennedy, 35th 1961–1963

DR ALTON OCHSNER

JUDYTH VARY BAKER

Dr Alton Ochsner

Dr Mary Sherman



Lee Harvey Oswald

Judyth Vary Baker

Judyth Vary Baker, 1963

- Worked in primitive conditions
  - Presence was off the records
- RPMI1640 tissue culture medium
- Experience with primates
- GOF SV40 cancer cells
  - Linear particle accelerator
- Inject a human “volunteer”
- Blew the whistle, endangering her life

The Weaponization of Cancer
The Monkey Virus
and The Kennedy Assassination

LEE HARVEY OSWALD and ME

Updated 2nd Edition

BY

JUDYTH VARY BAKER

Based on the best-selling
JFK assassination book *ME & LEE*

Foreword by Robert K. Tanenbaum
Afterword by Mark R. Mueller

DAVID FERRIE

Mafia Pilot, Participant in
Anti-Castro Bioweapon Plot,
Friend of Lee Harvey Oswald and
Key to the JFK Assassination

JUDYTH VARY BAKER

Author of
ME & LEE – HOW I CAME TO KNOW, LOVE AND LOSE LEE HARVEY OSWALD

Foreword by JESSE VENTURA


Cut-away diagram of a three-story-tall 1960s-era
LINEAR PARTICLE ACCELERATOR
Chamber for the platinum pyramid beam-splitter which redirects high-energy radiation to multiple chambers is seen at bottom.
Representation of the machine at Oxford, England


Dr. Mary's Monkey
How the unsolved murder of a doctor, a secret laboratory in New Orleans and cancer-causing monkey viruses are linked to Lee Harvey Oswald, the JFK assassination and emerging global epidemics
EDWARD T. HASLAM
FOREWORD BY
JIM MARRS

WHAT HAPPENED TO THE BIOWEAPON?

Banner
MD Anderson
~~Cancer~~ Center
Making Cancer History®

M. D. ANDERSON Foundation

There is no OS subject file on the M. D. ANDERSON Foundation but OS indices reflect a file on the M. D. ANDERSON Hospital and Tumor Institute.

A study program to determine the effects in diverse Biological Systems resulting from exposure to high intensity coherent radiation was contracted with the M.D. ANDERSON Hospital and Tumor Institute, University of Texas, Houston, Texas in October 1963 but as of 16 April 1964 there was a hold order against going ahead with the contract because of a question as to why the Agency should bear the whole cost of the contract which was to be for inter-departmental use. In May 1967 a note in the file indicated that M. D. ANDERSON Hospital and Tumor Institute will be engaged in classified work for the Agency. There was no record of a clearance issued.

MARSHALL FOUNDATION

See attached memorandum dated 30 January 1967 from Chief, Central Cover Group to Deputy Director, Plans - "Threat of Exposure of Agency Operations". The MARSHALL Foundation of Houston, Texas is considered one of the most vulnerable to exposure.

Dr Mary's Monkey , by Edward T Haslam. Page 304

SIV is the Simian Immunodeficiency Virus, one of several monkey viruses known to have contaminated the polio vaccine. The more carcinogenic SV-40 has received most of the press.

SIV, a single-strand RNA retrovirus, is considerably smaller than SV-40 (a double-strand DNA virus). The technology of the 1950s was not able to filter SIV from the viral extracts. Further, researchers of the day did not consider retroviruses to be dangerous, so they basically ignored them. AIDS has taught us how dangerous retroviruses can be.

If "the project" in New Orleans was intentionally exposing SV-40 to radiation, they may have exposed SIV to radiation at the same time. Simply stated, HIV-1 is a mutated form of SIV.

Did the mutation which changed SIV into HIV-1 occur when SV-40 was exposed to radiation? Was this the moment of conception of AIDS? Could this artificially-induced mutation explain why HIV-1 is mutating so rapidly? Why it is behaving so "unnaturally"? If you are a scientist involved in AIDS research, these are the questions I would like you to consider.

But due to the sheer number of runs, a dangerous biological weapon was being crafted. Originally, these viruses came from monkeys, with enhanced function developed through mutations caused by radiation. The star of the show was the SV-40 monkey virus – the same infamous carcinogenic virus that had contaminated the polio vaccines in the 1950's. But we didn't have the sophistication, in 1963, to isolate just this virus. Cross-infections between species, let alone monkeys, was common. The virulent mix of carcinogenic viruses that had been created in the past year contained an unknown number of original and mutated viruses. All that mattered is that it could *kill*—rapidly. Since I had produced lung cancer in my germ-free mice in a mere week, no wonder Dr. Ochsner, who ran this project, brought me in.

Our newborn mice, with immune systems unable to resist these hyped-up cancer viruses, were also being subjected to high-voltage radiation. The method induced mutation *in vivo* as well. These inoculated, irradiated mice were returned to the Mouse House, where those with the fastest-growing tumors were sent to Dave's kitchen lab, to start the whole process over again. It was an endless loop, with Dr. Mary and others selecting the most vicious of the cancer lines for more work. Precisely *what these mutated monkey viruses had become* was unknown.

Isolation of a Type D Retrovirus from B-Cell Lymphomas of a Patient with AIDS

ROBERT C. BOHANNON,[1,2] LAWRENCE A. DONEHOWER,[1] AND RICHARD J. FORD[2]*

Division of Molecular Virology, Baylor College of Medicine,[1] and Department of Molecular Pathology, University of Texas M. D. Anderson Cancer Center,[2] Houston, Texas 77030

Bohannon 1991

Received 29 November 1990/Accepted 23 July 1991

PMID: 1717707

An atypical syncytial variant of a high-grade Burkitt's-type B-cell lymphoma from a patient with AIDS who was seropositive for human immunodeficiency virus type 1 was studied. A productive type D retrovirus infection was identified in early-passage cell lines derived from two lymphomas from this patient. Nucleotide and amino acid sequence analysis as well as immunologic reactivity indicated that the isolated virus was highly related to Mason-Pfizer monkey virus (MPMV). MPMV is an immunosuppressive type D retrovirus that causes an AIDS-like syndrome in rhesus macaques. Amplification of DNA from the patient's diagnostic bone marrow

Anchorage Times March 5, 1992

Scientist links AIDS to early polio vaccines

By JEFF FRANKS
REUTERS

HOUSTON — A researcher said Wednesday he had found evidence old polio vaccines used in the 1950s carried a virus that causes AIDS in monkeys, a discovery that could explain how the disease entered the human population.

Robert Bohanon, a molecular virologist and president of a company developing AIDS test kits, told Reuters some stocks of polio vaccines used in Chicago in the mid-1950s have tested positive for the monkey virus.

"It might explain why and how the virus has gotten to humans," he said.

The possible link between polio vaccines and AIDS is investigated in a story by Houston writer Tom Curtis in the current issue of Rolling Stone magazine.

RE-WILDING OF MONKEYS

Synthetic Viral Genomics: Risks and Benefits for Science and Society

2006

Ralph S. Baric

University of North Carolina at Chapel Hill

https://www.jcvi.org/sites/default/files/assets/projects/synthetic-genomics-options-for-governance/Baric-Synthetic-Viral-Genomics.pdf

Cite as:

Baric RS. 2006. Synthetic Viral Genomics. In: *Working Papers for Synthetic Genomics: Risks and Benefits for Science and Society*, pp. 35-81. Garfinkel MS, Endy D, Epstein GL, Friedman RM, editors. 2007.

2006

of pathogens, limiting future attempts to newly emerged viruses. If notoriety, fear and directing foreign government policies are principle objectives, then the release and subsequent discovery of a synthetically derived virus bioweapon will certainly garner tremendous media coverage, inspire fear and terrorize human populations and direct severe pressure on government officials to respond in predicted ways.

2006

available in Genbank. A large number of recombinant viruses have been assembled using reverse genetic approaches including chimeric flaviviruses, chimeric enteroviruses and coronaviruses, HIV, lentiviruses and others usually for the purposes of generating vaccines or dissecting basic questions about, e.g., viral metabolism (29, 34, 39, 40, 50). Importantly, recombinant viruses are actively being designed with programmed pathogenic traits as a means of controlling certain insect and animal pests, providing both theoretical and practical strategies for conducting effective biowarfare (53, 68). More importantly, the identification of numerous virus virulence genes that target the innate immune response (e.g., interferons, tumor necrosis factors, interleukins, complement, chemokines, etc.), apoptosis (programmed cell death) and other host signaling pathways provides a gene repository that can be used to potentially manage virus virulence (5, 8, 9,

Scenario Narratives

LOCK STEP

A world of tighter top-down government control and more authoritarian leadership, with limited innovation and growing citizen pushback

https://www.nommeraadio.ee/meedia/pdf/RRS/Rockefeller%20Foundation.pdf

Sequencing the Pfizer monovalent mRNA vaccines also reveals dual copy 72-bp SV40 Promoter

ANANDAMIDE
APR 13, 2023

"Both monovalent and bivalent Pfizer vaccines contain 2 copies of the 72bp Enhancer in the SV40 promoter."





Further Sequencing of Pfizer lots

FL8095, EW0164, EW0173

ANANDAMIDE
SEP 26, 2025

← Post

Kevin McKernan ✓
@Kevin_McKernan

1763bp fragment in Pfizer EW0164
contains the whole SV40 ori, promter, enhancer, with the F1 Ori and part of the Neo/Kan gene

qPCR for SV40, Spike and Ori.

Note pediatric lots are 2X concentrated.



Translational Oncology 13 (2020) 100814

Contents lists available at ScienceDirect

Translational Oncology

journal homepage: www.elsevier.com/locate/tranon

S2 Subunit of SARS-nCoV-2 Interacts with Tumor Suppressor Protein p53 and BRCA: an In Silico Study

Singh 2020
PMID: 32619819

HIV entry protein plus neurotoxins



D

Cheng 2020 PMID: 32989130

SARS-CoV-2 S Protein (674-685)	Y	Q	T	Q	T	N	S	P	R	R	A	R
α-cobratoxin (*Naja naja*)	C	D	G	F	C	S	S	.	R	G	K	R
α-bungarotoxin	C	D	A	F	C	S	S	.	R	G	K	V
Rabies Virus G Protein (189-199)	C	D	I	F	T	N	S	.	R	G	K	R
α-cobratoxin (*Naja kaouthia*)	C	D	A	F	C	S	I	.	R	G	K	R
HIV-1 gp120 (164-174)	F	N	I	S	T	S	I	.	R	G	K	V

Synthetic Peptides Corresponding to Sequences of Snake Venom Neurotoxins and Rabies Virus Glycoprotein Bind to the Nicotinic Acetylcholine Receptor

Lentz 1987 PMID: 3448605

Thomas L. Lentz,[1] Edward Hawrot,[2] and Paul T. Wilson[1]

[1]Departments of Cell Biology and [2]Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06510

2 COBRAS, KRAIT, HIV-1 GP120, AND A RABIES PROTEIN





Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation

Cheng 2020
PMID: 32989130

GP120 NATURAL OCCURRENCE? ANOTHER SCANDAL?

February 2020

Cold Spring Harbor Laboratory

bioRxiv

THE PREPRINT SERVER FOR BIOLOGY

Follow this preprint

Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag

Prashant Pradhan, Ashutosh Kumar Pandey, Akhilesh Mishra, Parul Gupta, Praveen Kumar Tripathi, Manoj Balakrishnan Menon, James Gomes, Perumal Vivekanandan, Bishwajit Kundu

doi: https://doi.org/10.1101/2020.01.30.927871

PRADHAN QUOTES

- *Our results highlight astonishing relation between the gp120 and Gag protein of HIV, with 2019-nCoV spike glycoprotein. These are critical for the viruses to identify and latch on to their host cells and for viral assembly.*
- *Our findings suggest unconventional evolution for 2019-nCoV that warrants further investigation.*



Figure 3. Modelled homo-trimer spike glycoprotein of 2019-nCoV virus. The inserts from HIV envelop protein are shown with colored beads, present at the binding site of the protein.

COMMON FEATURES

HIV

- ADAM10
- ADAM17
- CD147
- Gp120 protein
  - LFA1
- Neuropilin 1

SARS-COV-2

- ADAM10
- ADAM17
- CD147
- Gp120 protein
  - LFA1
- Neuropilin 1

GOF CLUSTERBOMB

- Receptor attachment enhancement
- Immunological suppression
- Superantigen: toxic load, various sources—inflammation, cytokines
- Furin cleavage site
- Other spike insults
- Plasmid remnants
  - SV40
    - P53 suppression



THE SUCKER PUNCH

- Radiation
- Chemical poisons

More aggressive cancer

DOES SV40 BLOCK THE EFFECT OF CANCER "TREATMENTS"?

- . Pediatric brain cancers and other solid cancers have been found to contain SV40. SV40 binds with the tumor suppressor genes p53 and RB and stops tumor cells from undergoing apoptosis (programmed cell death)

- S.D. Conzen, et al, *Identification of a novel antiapoptotic functional domain in simian virus 40 large T antigen*, J Virol. 1997 Jun;71(6):4536-43; J.W. Ludlow, *Interactions between SV40 large-tumor antigen and the growth suppressor proteins pRB and p53,*FASEB J. 1993 Jul;7(10):866-71; Michele Carbone, et al., *The pathogenesis of mesothelioma*, Semin Oncol. 2002 Feb;29(1):2-17.

LETTER TO SENATOR BURTON CONTINUES….

- Exposing SV40 positive cancer cells to chemo and radiation does not kill the cells but simply creates more genetic mutations - making the cancer more aggressive. The bottom-line is that SV40 causes human cancer, stops orthodox cancer therapies (i.e. chemo and radiation) from providing any benefit, and can make the cancer even more aggressive.

http://www.ouralexander.org/BurtonSV40%20Letter%20(2003).doc


Facebook.com/BizarroComics
Sometimes, even if I stand in the middle of the room, no one acknowledges me.
ROCOMICS.COM Dist. by King Features

IN HONOR OF:

Dr Bernice Eddy

Dr J Anthony Morris

Judyth Vary Baker